ライフサイエンスコーパス: bone marrow transplantation

1 on criteria with a mean age of 13.4 years at bone marrow transplantation.

2 ibuted to atherogenesis in a murine model of bone marrow transplantation.

3 rough bone marrow stromal cells evidenced by bone marrow transplantation.

4 requiring lifelong transfusion or allogeneic bone marrow transplantation.

5 f malignant cells, the therapeutic intent of bone marrow transplantation.

6 g recovery of the hematopoietic system after bone marrow transplantation.

7 ymphopenias and hinder T cell recovery after bone marrow transplantation.

8 ve oxygen species (ROS) following allogeneic bone marrow transplantation.

9 opoietic chimerism and T cell deletion after bone marrow transplantation.

10 itical role of donor sleep in the success of bone marrow transplantation.

11 ponses in leukemia patients after allogeneic bone marrow transplantation.

12 prevention of GVHD in preclinical models of bone marrow transplantation.

13 ant in many clinical applications, including bone marrow transplantation.

14 erapeutic responses of an NPC2 patient after bone marrow transplantation.

15 uring hematopoietic reconstitution following bone marrow transplantation.

16 oughout life and are the functional units of bone marrow transplantation.

17 duals with diarrhea after they had undergone bone marrow transplantation.

18 en gained adaptive immunity after undergoing bone marrow transplantation.

19 d including mono and/or polychemotherapy and bone marrow transplantation.

20 gimens to improve the safety and efficacy of bone marrow transplantation.

21 e repopulated to a normal level by syngeneic bone marrow transplantation.

22 is a critical complication after allogeneic bone marrow transplantation.

23 iTregs) for the induction of tolerance after bone marrow transplantation.

24 GVHD) is the main complication of allogeneic bone marrow transplantation.

25 sease following sex-mismatched HLA-identical bone marrow transplantation.

26 reconstitution of hematopoiesis upon serial bone marrow transplantation.

27 as partially reduced and then recovered upon bone marrow transplantation.

28 r restrict alloreactivity after experimental bone marrow transplantation.

29 lls were severely compromised in competitive bone marrow transplantation.

30 Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation.

31 ecific P2X(7)-deficient animals generated by bone marrow transplantation.

32 rrected the T cell lymphopenia in mice after bone marrow transplantation.

33 er remission, and requirement for allogeneic bone marrow transplantation.

34 scence protein transgenic mice were used for bone marrow transplantation.

35 n this patient, who had undergone successful bone marrow transplantation.

36 r T cells after allogeneic but not syngeneic bone marrow transplantation.

37 (GVHD) is a major complication of allogeneic bone marrow transplantation.

38 HC class I-restricted T-cell responses after bone marrow transplantation.

39 the conditioning regimen, and declined after bone marrow transplantation.

40 sed quiescence and increased HSC activity in bone marrow transplantation.

41 activated in the lung and other organs after bone marrow transplantation.

42 tosomal recessive HIES and only curable with bone marrow transplantation.

43 LRP6 in multiple murine models of allogeneic bone marrow transplantation.

44 val of one patient, who underwent successful bone marrow transplantation.

45 , dermatologic conditions, or solid-organ or bone marrow transplantation.

46 sident beds that could not be transferred by bone marrow transplantation.

47 , both in physiological conditions and after bone marrow transplantation.

48 th lentivirus expressing Hmga2 and performed bone marrow transplantation.

49 changes during stress hematopoiesis, such as bone marrow transplantation.

50 her models, including whole-body irradiation/bone-marrow transplantation.

51 stion of long-term HSC function along serial bone marrow transplantations.

52 h donor-recipient compatibility in organ and bone marrow transplantations.

53 iology was 47.2% (95% CI, 34.3-59.1) and for bone marrow transplantation 22.8% (95% CI, 8.7-40.8).

54 ents (97 eyes) who developed cataracts after bone marrow transplantation, 4 patients (6 eyes) require

55 (Tc1) or Tc17 cells combined with autologous bone marrow transplantation after total body irradiation

56 One child underwent bone marrow transplantation aged 9 months, with apparent

57 Allogeneic bone marrow transplantation (allo-BMT) is a curative the

58 s remains the major limitation of allogeneic bone marrow transplantation (allo-BMT).

59 of the major complications after allogeneic bone marrow transplantation (allo-BMT).

60 effects following MHC-mismatched allogeneic bone marrow transplantation (allo-BMT).

61 (GVHD), a serious complication of allogeneic bone marrow transplantation (allo-BMT).

62 th a STAT6 inhibitor and IL-4(-/-)IL-13(-/-) bone marrow transplantation also protected against Schis

63 Allogeneic bone marrow transplantation, although limited by donor a

64 mpared with 58% and 46% after haploidentical bone marrow transplantation and 59% and 52% after periph

65 Using bone marrow transplantation and Cre recombinase-based li

66 in vivo, we generated CD36 chimeric mice by bone marrow transplantation and evaluated the two models

67 scle injury model combined with irradiation, bone marrow transplantation and in vivo imaging, we show

68 The combination of bone marrow transplantation and local muscle radiation p

69 apeutic avenues, and some of them, including bone marrow transplantation and mesenchymal stem cell th

70 First, we performed adoptive bone marrow transplantation and observed that introducti

71 t mice, we tracked blood-borne miR-210 using bone marrow transplantation and parabiosis (conjoining o

72 Bone marrow transplantation and platelet depletion/recon

73 Bone marrow transplantation and platelet transfusion stu

74 ile the patient received cancer treatment, a bone marrow transplantation, and antibiotics up to the p

75 mouse models of cancer, infectious disease, bone marrow transplantation, and autoimmune disease.

76 ents using pancreas-specific Perk knockouts, bone marrow transplantation, and cultured pancreatic isl

77 GvHD) is a common complication of allogeneic bone marrow transplantation, and has a major effect on t

78 el of GN was studied in AREG(-/-) mice after bone marrow transplantation, and in mice with myeloid ce

79 be presented by the CD8(-) cDC subset after bone marrow transplantation, and inflammation during GVH

80 reatment, including chemotherapy, radiation, bone marrow transplantation, and newer modalities such a

81 also limits T lineage regeneration following bone marrow transplantation, and so contributes to the s

82 These data have implications for successful bone marrow transplantation, and suggest that tolerance

83 Corticosteriod therapy and bone marrow transplantation are common treatment options

84 alloreactive donor T cells after allogeneic bone marrow transplantation are limited by a concomitant

85 Bone marrow transplantation assays reveal that enhanced

86 Bone marrow transplantation assays suggest that systemic

87 a levels accelerates MLL-AF9-mediated AML in bone marrow transplantation assays.

88 logenous leukemia (AML) with long latency in bone marrow transplantation assays.

89 athies can be cured with allogeneic blood or bone marrow transplantation, availability of matched don

90 BO blood group mismatched solid organ and/or bone marrow transplantation between donor and recipient.

91 Reciprocal bone marrow transplantation between KitW/Wv and KitWsh/W

92 In this study, we performed bone marrow transplantations between age-mismatched dono

93 ostasis and thrombosis, we performed crossed bone marrow transplantations between C57BL/6J and Vwf(-/

94 in [ATG]) facilitates immune tolerance after bone marrow transplantation (BMT) across major histocomp

95 t donor-recipient immune tolerance following bone marrow transplantation (BMT) across MHC barriers vi

96 cause of late mortality following allogeneic bone marrow transplantation (BMT) and is characterized b

97 transplantation (VCA) with chimerism through bone marrow transplantation (BMT) are currently being pu

98 Colony forming/replating and bone marrow transplantation (BMT) assays showed that Alo

99 ficantly improves survival (P < .0001) after bone marrow transplantation (BMT) by inhibiting the init

100 However, LT is not curative and only bone marrow transplantation (BMT) can correct the underl

101 Neonatal bone marrow transplantation (BMT) could offer a novel th

102 rineurial microenvironment using a series of bone marrow transplantation (BMT) experiments in transge

103 Bone marrow transplantation (BMT) for class 3 patients w

104 We developed preclinical models of bone marrow transplantation (BMT) for MM using Vk*MYC my

105 CMV viremia in a Cynomolgus macaque model of bone marrow transplantation (BMT) for tolerance inductio

106 emia (ALL) persisting or relapsing following bone marrow transplantation (BMT) has a dismal prognosis

107 Indeed, bone marrow transplantation (BMT) has its genesis in rod

108 including alveolar macrophages (AMs), after bone marrow transplantation (BMT) have impaired host def

109 eir therapeutic potential following congenic bone marrow transplantation (BMT) in a proteoglycan-indu

110 ed virus (AAV)2/5-mediated gene therapy with bone marrow transplantation (BMT) in the INCL mouse.

111 nd to host alloantigens following allogeneic bone marrow transplantation (BMT) induce graft-versus-ho

112 lignant hematological disorders, HLA-matched bone marrow transplantation (BMT) is curative.

113 However, simultaneous kidney or VCA and bone marrow transplantation (BMT) is problematic because

114 Bone marrow transplantation (BMT) is the other therapeut

115 Here we show that bone marrow transplantation (BMT) of PARP-knockout (PARP

116 f pediatric obesity may significantly affect bone marrow transplantation (BMT) outcomes.

117 Bone marrow transplantation (BMT) performance can be lim

118 Because bone marrow transplantation (BMT) results in decreased c

119 in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intestinal inflam

120 vere and frequent complication of allogeneic bone marrow transplantation (BMT) that involves the gast

121 n DNA-PKcs(3A/3A) mutant mice, which require bone marrow transplantation (BMT) to prevent early morta

122 nt study, chimeric mice were created through bone marrow transplantation (BMT) using wild-type and CX

123 Bone marrow transplantation (BMT) was performed from don

124 Haploidentical bone marrow transplantation (BMT) with 300 muCi (90)Y-an

125 recently achieved in the clinic by combining bone marrow transplantation (BMT) with kidney transplant

126 revents successful outcomes after allogeneic bone marrow transplantation (BMT), an effective therapy

127 is a major cause of mortality in allogeneic bone marrow transplantation (BMT), for which administrat

128 fe-threatening complication after allogeneic bone marrow transplantation (BMT), particularly in the p

129 Here we use bone marrow transplantation (BMT), total body irradiatio

130 Using murine models of bone marrow transplantation (BMT), we find that MHCII(-/

131 versus-host disease (aGvHD) after allogeneic bone marrow transplantation (BMT).

132 d a mouse MLIV model to test the efficacy of bone marrow transplantation (BMT).

133 ns a major complication following allogeneic bone marrow transplantation (BMT).

134 s-tumor [GVT]) in cancer patients undergoing bone marrow transplantation (BMT).

135 minish GVL, leading to greater relapse after bone marrow transplantation (BMT).

136 hogenesis of graft-versus-host disease after bone marrow transplantation (BMT).

137 anced hematopoietic reconstitution following bone marrow transplantation (BMT).

138 esents a major complication after allogeneic bone marrow transplantation (BMT).

139 raft-versus-leukemia (GVL) effects following bone marrow transplantation (BMT).

140 mune hepatitis (AIH) has been reported after bone marrow transplantation (BMT).

141 tivity represents a highly desirable goal in bone marrow transplantation (BMT).

142 HD in the gut in murine models of allogeneic bone marrow transplantation (BMT).

143 opment in euthymic and athymic recipients of bone marrow transplantation (BMT).

144 revealed genetic chimerism in patients after bone marrow transplantation (BMT).

145 eterminant of lethality following allogeneic bone marrow transplantation (BMT).

146 cord blood transplantation (CBT, n = 96) or bone marrow transplantation (BMT, n = 389).

147 rm-specific betaAR knockout (betaARKO) or WT bone-marrow transplantation (BMT) and after full reconst

148 Bone marrow transplantation (BMTx), kidney transplantati

149 in a dose-dependent manner after allogeneic bone marrow transplantation, both in donor-derived CD4(+

150 invasive candidiasis in patients undergoing bone marrow transplantation but is not approved for use

151 lethal and morbid complication of allogeneic bone marrow transplantation, but GVHD is tightly linked

152 patients hospitalized to receive allogeneic bone marrow transplantation can persist for weeks, but l

153 With bone marrow transplantation, circulating miR-210 was der

154 Bone marrow transplantation combined with ACT of antitum

155 awa and Kabashima) address the issue whether bone marrow transplantation could be applied to patients

156 AB vector system when combined together with bone marrow transplantation could quickly knock down c-k

157 Irradiation and bone marrow transplantation did not further affect body

158 In one patient who previously received bone marrow transplantation, different minor allele freq

159 After bone marrow transplantation, donor-derived immune cells

160 Lsh-deficient mice without bone marrow transplantation exhibited lower Ig levels in

161 Bone marrow transplantation experiments confirmed that t

162 Bone marrow transplantation experiments demonstrated tha

163 Bone marrow transplantation experiments identify hematop

164 Through bone marrow transplantation experiments in a transgenic

165 Bone marrow transplantation experiments indicated that A

166 Bone marrow transplantation experiments isolated the att

167 Bone marrow transplantation experiments revealed that en

168 Bone marrow transplantation experiments revealed that no

169 Furthermore, bone marrow transplantation experiments revealed that T

170 Bone marrow transplantation experiments revealed that th

171 Bone marrow transplantation experiments revealed that th

172 Bone marrow transplantation experiments revealed that TL

173 Similarly, adoptive transfer and bone marrow transplantation experiments showed different

174 Bone marrow transplantation experiments showed that the

175 Bone marrow transplantation experiments suggest that REG

176 Macrophage depletion and bone marrow transplantation experiments validated the fu

177 Bone marrow transplantation experiments were performed t

178 Lung transcriptomics, bone marrow transplantation experiments, and analysis of

179 In bone marrow transplantation experiments, the development

180 Bone marrow transplantation failed to rescue outgrowth.

181 Murine-competitive bone marrow transplantation followed by treatment with A

182 safely replaced with hydroxyurea therapy or bone marrow transplantation for a cohort of children wit

183 visable before commencing clinical trials of bone marrow transplantation for epidermolysis bullosa si

184 uggest that engraftment after haploidentical bone marrow transplantation for haemoglobinopathies is p

185 vices to only provide payment for allogeneic bone marrow transplantation for patients with sickle cel

186 ylaxis for both acute and chronic GVHD after bone marrow transplantation from HLA-matched donors.

187 tantly, in vivo thrombosis experiments after bone marrow transplantation from platelet-specific ERK5

188 Engraftment was faster after bone marrow transplantation from siblings and was associ

189 ences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors.

190 cardiac hypertrophy or dysfunction, whereas bone marrow transplantation from wild-type mice into mic

191 ion of the intrinsic pathway of coagulation, bone marrow transplantation from WT mice or provision of

192 Neither irradiation nor bone marrow transplantation had any effect on the 40% di

193 r-deficient, LDLr(-/-) chimeras, obtained by bone marrow transplantation, had smaller but, paradoxica

194 atched, or HLA-haploidentical, related donor bone marrow transplantation (haploBMT) has seen a reviva

195 Allogeneic bone marrow transplantation has been attempted in severe

196 apy and immunomagnetically purged autologous bone marrow transplantation has been shown to improve ou

197 tment or cure for epidermolysis bullosa, but bone marrow transplantation has been suggested to improv

198 Bone marrow transplantation has resulted in life-saving

199 We also found that after bone marrow transplantation, host macrophages retained t

200 regimen to improve the outcome of unrelated bone marrow transplantation in Fanconi anemia (FA).

201 Osteopetrosis can be partially treated by bone marrow transplantation in humans and mice(11-18), c

202 Finally, WT bone marrow transplantation in IL10KO mice inhibited tra

203 g graft-versus-host disease after allogeneic bone marrow transplantation in mice.

204 use of high-dose chemotherapy and autologous bone marrow transplantation in patients with malignant d

205 Reciprocal bone marrow transplantation in sublethally irradiated mi

206 lfan-based chemotherapy regimen was used for bone marrow transplantation in wild-type mice before sub

207 uential exposure to chemotherapy, and serial bone marrow transplantation increased senescence in anim

208 e marrow cells and increases chimerism after bone marrow transplantation, indicating that Scl is also

209 ditional Stat3 knockout strain and performed bone marrow transplantations into lethally irradiated re

210 Bone marrow transplantation is associated with a high ri

211 Bone marrow transplantation is currently the only curati

212 Bone marrow transplantation is the only curative therapy

213 Allogeneic bone marrow transplantation is under investigation for a

214 Bone-marrow transplantation is an effective cell therapy

215 tress, such as during anticancer therapy and bone marrow transplantation, is of clinical significance

216 Hematopoietic chimerism after allogeneic bone marrow transplantation may establish a state of don

217 Following bone marrow transplantation, mice were fed a high-fat di

218 this devastating disorder, and suggest that bone marrow transplantation might offer a feasible thera

219 In a murine bone marrow transplantation model, the coexpression of S

220 In a murine bone marrow transplantation model, the differential migr

221 In a bone marrow transplantation model, the interaction betwe

222 thal myeloproliferative disorder in a murine bone marrow transplantation model.

223 ed, parent-->F1, and miHAg-mismatched murine bone marrow transplantation models.

224 sed for GVHD prevention in murine allogeneic bone marrow transplantation models.

225 We also established a novel bone marrow transplantation mouse model to test whether

226 The role of combination therapies and bone marrow transplantation needs further investigation.

227 Bone marrow transplantation not only rescued hematopoies

228 Bone marrow transplantation of Apoe(-/-) Malat1(-/-) bon

229 85beta resulted in increased mast cells, and bone marrow transplantation of cells overexpressing p85b

230 We performed isogenic bone marrow transplantation of inducible sphingosine-1-p

231 atopoietic cell intrinsic activity of Itfg2, bone marrow transplantation of Itfg2-deficient cells was

232 specific knockout of the insulin receptor or bone marrow transplantation of mutant TLR4 marrow cells

233 targets to enhance platelet production after bone marrow transplantation or chemotherapy.

234 othyroidism in contrast to mice treated with bone marrow transplantation or gene therapy.

235 mprovements in conventional chemotherapy and bone marrow transplantation, overall survival remains po

236 Bone marrow transplantation partially attenuated hypokin

237 In addition, 9 months after bone marrow transplantation, patient 1 had Hashimoto thy

238 We developed a nonmyeloablative bone marrow transplantation platform using related, incl

239 ation allowed the patient to be referred for bone marrow transplantation, potentially curative for hi

240 By using a reciprocal bone marrow transplantation procedure between wild-type

241 nockdown in macrophages using transgenic and bone marrow transplantation procedures to blunt HFD-indu

242 a comparison arm with patients not receiving bone marrow transplantation prompted the closure of this

243 us cells might interfere with the outcome of bone marrow transplantation, protocols usually include c

244 es of hematopoietic reconstitution following bone marrow transplantation provide a window of opportun

245 lication after peripheral blood stem cell or bone marrow transplantation, rarely occurs in kidney and

246 marrow-derived cells migrate to the skin of bone marrow transplantation recipient mice, but these ce

247 ively analyzed in 34 NHP combined kidney and bone marrow transplantation recipients which were divide

248 lly lose function following transfer to male bone marrow transplantation recipients, we have explored

249 ficant morbidity and mortality in cancer and bone marrow transplantation recipients.

250 Bone marrow transplantation recreated the haemopoietic p

251 Bone marrow transplantation remains the only cure for PN

252 Bone marrow transplantation reproduced these phenotypic

253 Bone marrow transplantation rescued the anemia phenotype

254 Studies on mice after bone marrow transplantation revealed that CD73 present o

255 Bone marrow transplantation revealed that certain featur

256 Bone marrow transplantations revealed a strong cell intr

257 er intracranial injections of AAV2/5-PPT1 or bone marrow transplantation, separately as well as in co

258 t3-deficient mice, was less prominent in the bone marrow transplantation setting, possibly by limitin

259 Bone marrow transplantations show that the platelet phen

260 a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to tra

261 Bone marrow transplantation studies and mixed bone marro

262 Reciprocal bone marrow transplantation studies and myeloid cell-spe

263 Bone marrow transplantation studies demonstrated that lo

264 Last, we performed bone marrow transplantation studies in Rag-5xfAD mice, r

265 Importantly, bone marrow transplantation studies revealed an essentia

266 Bone marrow transplantation studies revealed that Lsh de

267 Bone marrow transplantation studies show that expression

268 Finally, bone marrow transplantation studies were performed to de

269 colony-forming/replating assays and in vivo bone marrow transplantation studies, we show that forced

270 e utilized in modulation of HSC activity and bone marrow transplantation studies.

271 s required on cells that are not replaced by bone marrow transplantation, such as vascular endothelia

272 Bone marrow transplantation therapy relies on the life-l

273 LL-fusion-mediated leukemogenesis in primary bone marrow transplantation through suppressing Hoxa9/Me

274 mised patients with blood disorders or after bone marrow transplantation to achieve antiviral control

275 patients needing LT should be considered for bone marrow transplantation to achieve cure.

276 Some women suffering from leukemia require bone marrow transplantation to be cured.

277 In addition, we used bone marrow transplantation to generate sickle mice defi

278 Using experimental bone marrow transplantation to model immune-mediated GI

279 approaches to augment host B7-H3 early after bone marrow transplantation to prevent GVHD and to devel

280 trained granulopoiesis was transmissible by bone marrow transplantation to recipient naive mice.

281 der, and patients are treated primarily with bone marrow transplantation to restore hematopoietic fun

282 Furthermore, we used bone marrow transplantation to reveal that CAMK2gamma in

283 ne therapy, substrate reduction therapy, and bone marrow transplantation to target the primary pathog

284 during a period of immunocompromise after a bone marrow transplantation to treat hypodiploid leukemi

285 ws efficacy in mouse models of recovery from bone marrow transplantation, ulcerative colitis, and par

286 Nine intensive care and bone marrow transplantation units in six hospitals were

287 g lung allograft tolerance with tandem donor bone marrow transplantation using a short-duration nonmy

288 Bone marrow transplantation using wild-type C57BL/6 dono

289 re model was more equivocal, so experimental bone marrow transplantation was used to examine hematopo

290 Using bone marrow transplantation, we determined that hematopo

291 Using bone marrow transplantation, we present evidence that th

292 me polymerase chain reaction, and reciprocal bone marrow transplantation were used to evaluate the ef

293 ppression is most profound during GVHD after bone marrow transplantation where an inflammatory cytoki

294 y from myeloablative challenge and following bone marrow transplantation, whereas BCL-XL was dispensa

295 sease (GVHD) is a complication of allogeneic bone marrow transplantation whereby transplanted naive a

296 hes were applied in AD+ mice: (i) ACE10/GFP+ bone marrow transplantation with head shielding; and (ii

297 ile maintaining the safety of haploidentical bone marrow transplantation with post-transplantation cy

298 hat non-myeloablative haploidentical related bone marrow transplantation with post-transplantation cy

299 iency virus or AIDS, or prior solid organ or bone marrow transplantation with receipt of chronic immu

300 dy of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates of s